Clinical pharmacology study of anti-parkinson's drug pramipexole

• Register: ChiCTR
• Last refreshed on: 18 April 2017
• Main ID: ChiCTR-TTRCC-12002751
• Date of registration: 2012-11-26
• Prospective Registration: No
• Primary sponsor: Institute of Clinical Pharmacology, Central South University
• Public title: Clinical pharmacology study of anti-parkinson's drug pramipexole
• Scientific title: A rondomised clinical trial of the potential drug-drug interaction between pramipexole and metformin
• Date of first enrolment: 2012-04-01
• Target sample size: A:18;B:18;
• Recruitment status: Completed
• URL: http://www.chictr.org.cn/showproj.aspx?proj=6803
• Study type: Interventional study
• Study design: Randomized cross-over control
• Phase: I (Phase I study)

Countries of recruitment

China

Contacts

• Name: Jie Liu, Huizi Wu

• Name: Huizi Wu
• Affiliation: Institute of Clinical Pharmacology, Central South University

Key inclusion & exclusion criteria

Inclusion criteria: 1.Healthy male volunteers aged between 18-30.
2. One month before the trial and during the trial the volunteers should not smoking, drinking and take any other drugs.
Exclusion criteria: 1.People who had history of disease and family medical history should exclude in this experiment;
2.People who used to drinking and smoking should exclude in this experiment.

Age minimum: 19
Age maximum: 26
Gender: Male

Health Condition(s) or Problem(s) studied

Parkinson's disease

Intervention(s)

A:Given pramipexole only;B:Given pramipexole and metformin simultaneously ;

Primary Outcome(s)

Drug concentratio;

Source(s) of Monetary Support

National Natural Science Foundation of China